We determined the renal radiation dose of a series of In-111-labeled peptides using animal SPECT. Because the animals' health deteriorated, renal toxicity was assessed. Methods: Wild-type and megalin-deficient mice were imaged repeatedly at 3- to 6-wk intervals to quantify renal retention after injection of 40-50 MBq of In-111-diethylenetriaminepentaacetic acid-labeled peptides (octreotide, exendin, octreotate, neurotensin, and minigastrin analogs), and the absorbed kidney radiation doses were estimated. Body weight, renal function parameters, and renal histology were determined at 16-20 wk after the first scan and compared with those in naive animals. Results: Because of high renal retention, In-111-diethylenetriaminepentaacetic acid-exend...
Item does not contain fulltextAIM: In peptide receptor radionuclide therapy (PRRT) using radiolabell...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs...
We determined the renal radiation dose of a series of (111)In-labeled peptides using animal SPECT. B...
We determined the renal radiation dose of a series of 111In-labeled peptides using animal SPECT. Bec...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Radiolabelled peptides used for peptide receptor radionuclide therapy are excreted mainly via the ki...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with beta-p...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with b-part...
Neuroendocrine tumors overexpressing somatostatin receptors can be treated with peptide-receptor rad...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
textabstractAim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin an...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
Aim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues, kid...
Item does not contain fulltextAIM: In peptide receptor radionuclide therapy (PRRT) using radiolabell...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs...
We determined the renal radiation dose of a series of (111)In-labeled peptides using animal SPECT. B...
We determined the renal radiation dose of a series of 111In-labeled peptides using animal SPECT. Bec...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Radiolabelled peptides used for peptide receptor radionuclide therapy are excreted mainly via the ki...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with beta-p...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with b-part...
Neuroendocrine tumors overexpressing somatostatin receptors can be treated with peptide-receptor rad...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
textabstractAim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin an...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
Aim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues, kid...
Item does not contain fulltextAIM: In peptide receptor radionuclide therapy (PRRT) using radiolabell...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs...